Drugs / MT-5547
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03245008 | Sep 2017 → Dec 2019 | osteoarthritis | Tanabe Pharma Corporation | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-5547 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03245008 ↗ |
| Route | Subcutaneous | “MT-5547 Subcutaneous (SC) dosing regimen 1.” NCT03245008 ↗ |